Hepatic Arterial Infusion of Cisplatin as a Single Agent or in Combination with Vinblastine for Breast Cancer Metastatic to the Liver
Breast cancer patients with hepatic metastases that are refractory to front-line chemotherapy respond poorly to additional systemic therapy. In a study of more than 100 patients treated with systemic continuous infusion vinblastine (V) we observed a 37% overall response rate, but responses were documented in only 13% of the hepatic metastases (1). Regional delivery may allow to increase the tumor exposure to suitable antitumor agents. The reported trials of intraarterial regional chemotherapy have generally shown some advantage for this delivery route (2).
KeywordsFatigue Toxicity Catheter Hydration Platinum
Unable to display preview. Download preview PDF.
- 2..Stephen, F.O. In: Recent Results in Cancer Research (Eds. K. Schwlemme and V. Aligner), Vol 86, pp. 1–12.Google Scholar